Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.

Journal of drugs in dermatology : JDD

Volumn 12, Issue 3, 2013, Pages

  Makino, Elizabeth T ^a   Mehta, Rahul C ^b   Garruto, John ^b   Gotz, Vincent ^b   Sigler, Monya L ^b   Herndon, James H ^b  

^a SkinMedica An Allergan Company   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; HYDROQUINONE; HYDROQUINONE DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; FACE; FEMALE; FOLLOW UP; HUMAN; HYPERPIGMENTATION; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; DERMATOLOGIC AGENTS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROQUINONES; HYPERPIGMENTATION; MIDDLE AGED; PROSTAGLANDIN ANTAGONISTS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84884387093     PISSN: 15459616     EISSN: None     Source Type: None    
DOI: None     Document Type: Article

References (0)